Relationship between amyloid-beta and the ubiquitin–proteasome system in Alzheimer’s disease

References

• Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Hikichi Y, Willuweit A, Shintani Y, Horiguchi T. FBL2 regulates amyloid precursor protein (APP) metabolism by promoting ubiquitination-dependent APP degradation and inhibition of APP endocytosis. J Neurosci. 2012;32:3352–65.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. The ubiquitin-proteasome system and signal transduction pathways regulating epithelial mesenchymal transition of cancer. J Biomed Sci. 2012;19:67.
   PubMedGoogle Scholar
• Gorodkiewicz E, Ostrowska H, Sankiewicz A. SPR imaging biosensor for the 20S proteasome: Sensor development and application to measurement of proteasomes in human blood plasma. Mikrochim Acta. 2011;175:177–84.
   PubMed Web of Science ®Google Scholar
• Schipper-Krom S, Juenemann K, Reits EA. The ubiquitin-proteasome system in Huntington’s disease: Are proteasomes impaired, initiators of disease, or coming to the rescue? Biochem Res Int. 2012;2012:837015.
   PubMedGoogle Scholar
• Riederer BM, Leuba G, Vernay A, Riederer IM. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp Biol Med (Maywood). 2011;236:268–76.
   PubMed Web of Science ®Google Scholar
• Wang CF, Huang YS. Calpain 2 activated through N-methyl-D-aspartic acid receptor signaling cleaves CPEB3 and abrogates CPEB3-repressed translation in neurons. Mol Cell Biol. 2012;32:3321–32.
   PubMed Web of Science ®Google Scholar
• Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181:1426–35.
   PubMed Web of Science ®Google Scholar
• Cecarini V, Bonfili L, Cuccioloni M, Mozzicafreddo M, Rossi G, Buizza L, . Crosstalk between the ubiquitin-proteasome system and autophagy in a human cellular model of Alzheimer's disease. Biochim Biophys Acta. 2012;1822:1741–51.
   PubMed Web of Science ®Google Scholar
• Zong C, Gomes AV, Drews O, Li X, Young GW, Berhane B, . Regulation of murine cardiac 20S proteasomes: Role of associating partners. Circ Res. 2006;99:372–80.
   PubMed Web of Science ®Google Scholar
• Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA. 1987;84:3033–6.
   PubMed Web of Science ®Google Scholar
• Saido T, Leissring MA. Proteolytic degradation of amyloid beta-protein. Cold Spring Harb Perspect Med. 2012;2:a006379.
   PubMed Web of Science ®Google Scholar
• Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E. Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol. 2003;180:131–43.
   PubMed Web of Science ®Google Scholar
• Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci. 2006;26:4277–88.
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang J. Amyloid-beta peptide is a substrate of the human 20S proteasome. ACS Chem Neurosci. 2010;1:655–60.
   PubMed Web of Science ®Google Scholar
• Gregori L, Hainfeld JF, Simon MN, Goldgaber D. Binding of amyloid beta protein to the 20 S proteasome. J Biol Chem. 1997;272:58–62.
   PubMed Web of Science ®Google Scholar
• van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, . Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science. 1998;279:242–7.
   PubMed Web of Science ®Google Scholar
• Fischer DF, van Dijk R, van Tijn P, Hobo B, Verhage MC, van der Schors RC, . Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. Neurobiol Aging. 2009;30:847–63.
   PubMed Web of Science ®Google Scholar
• Chadwick L, Gentle L, Strachan J, Layfield R. Review: unchained maladie – a reassessment of the role of Ubb(+1) -capped polyubiquitin chains in Alzheimer's disease. Neuropathol Appl Neurobiol. 2012;38:118–31.
   PubMed Web of Science ®Google Scholar
• van Tijn P, Dennissen FJ, Gentier RJ, Hobo B, Hermes D, Steinbusch HW, . Mutant ubiquitin decreases amyloid beta plaque formation in a transgenic mouse model of Alzheimer's disease. Neurochem Int. 2012;61:739–48.
   PubMed Web of Science ®Google Scholar
• Ko S, Kang GB, Song SM, Lee JG, Shin DY, Yun JH, . Structural basis of E2–25K/UBB+1 interaction leading to proteasome inhibition and neurotoxicity. J Biol Chem. 2010;285:36070–80.
   PubMed Web of Science ®Google Scholar
• Zhang D, Raasi S, Fushman D. Affinity makes the difference: Nonselective interaction of the UBA domain of Ubiquilin-1 with monomeric ubiquitin and polyubiquitin chains. J Mol Biol. 2008;377:162–80.
   PubMed Web of Science ®Google Scholar
• Stieren ES, El Ayadi A, Xiao Y, Siller E, Landsverk ML, Oberhauser AF, . Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J Biol Chem. 2011;286:35689–98.
   PubMed Web of Science ®Google Scholar
• Boehning D, Barral JM. Protein quality control in Alzheimer’s disease: The contentious role of ubiquilin-1. Future Neurol. 2012;7:5–8.
   Google Scholar
• El Ayadi A, Stieren ES, Barral JM, Boehning D. Ubiquilin-1 and protein quality control in Alzheimer disease. Prion. 2013;7:164–169.
   PubMed Web of Science ®Google Scholar
• Tank EM, True HL. Disease-associated mutant ubiquitin causes proteasomal impairment and enhances the toxicity of protein aggregates. PLoS Genet. 2009;5:e1000382.
   PubMedGoogle Scholar
• Lonskaya I, Shekoyan AR, Hebron ML, Desforges N, Algarzae NK, Moussa CE. Diminished parkin solubility and co-localization with intraneuronal amyloid-beta are associated with autophagic defects in Alzheimer's disease. J Alzheimers Dis. 2013;33:231–47.
   PubMed Web of Science ®Google Scholar
• Burns MP, Zhang L, Rebeck GW, Querfurth HW, Moussa CE. Parkin promotes intracellular Abeta1-42 clearance. Hum Mol Genet. 2009;18:3206–16.
   PubMed Web of Science ®Google Scholar
• Rosen KM, Moussa CE, Lee HK, Kumar P, Kitada T, Qin G, . Parkin reverses intracellular beta-amyloid accumulation and its negative effects on proteasome function. J Neurosci Res. 2010;88:167–78.
   PubMed Web of Science ®Google Scholar
• Khandelwal PJ, Herman AM, Hoe HS, Rebeck GW, Moussa CE. Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated Abeta in AD models. Hum Mol Genet. 2011;20:2091–102.
   PubMed Web of Science ®Google Scholar
• Solano RM, Casarejos MJ, Gomez A, Perucho J, de Yébenes JG, Mena MA. Parkin null cortical neuronal/glial cultures are resistant to amyloid-beta1-42 toxicity: A role for autophagy? J Alzheimers Dis. 2012;32:57–76.
   PubMed Web of Science ®Google Scholar
• Kaneko M, Okuma Y, Nomura Y. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: Possible involvement of HRD1, a novel molecule related to endoplasmic reticulum stress, in Alzheimer's disease. J Pharmacol Sci. 2012;118:325–30.
   PubMed Web of Science ®Google Scholar
• Kaneko M, Saito R, Okuma Y, Nomura Y. Possible involvement of ubiquitin ligase HRD1 insolubilization in amyloid beta generation. Biol Pharm Bull. 2012;35:269–72.
   PubMed Web of Science ®Google Scholar
• Tanabe C, Maeda T, Zou K, Liu J, Liu S, Nakajima T, . The ubiquitin ligase synoviolin up-regulates amyloid beta production by targeting a negative regulator of gamma-secretase, Rer1, for degradation. J Biol Chem. 2012;287:44203–11.
   PubMed Web of Science ®Google Scholar
• Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 2004;101:2173–8.
   PubMed Web of Science ®Google Scholar
• Watanabe T, von der Kammer H, Wang X, Shintani Y, Horiguchi T. Neuronal expression of F-box and leucine-rich-repeat protein 2 decreases over Braak stages in the brains of Alzheimer's disease patients. Neurodegener Dis. 2013;11:1–12.
   PubMed Web of Science ®Google Scholar
• Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, . Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem. 2004;279:13256–64.
   PubMed Web of Science ®Google Scholar
• Barrachina M, Castano E, Dalfo E, Maes T, Buesa C, Ferrer I. Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiol Dis. 2006;22:265–73.
   PubMed Web of Science ®Google Scholar
• Guglielmotto M, Monteleone D, Boido M, Piras A, Giliberto L, Borghi R, . Abeta1-42-mediated down-regulation of Uch-L1 is dependent on NF-kappaB activation and impaired BACE1 lysosomal degradation. Aging Cell. 2012;11:834–44.
   PubMed Web of Science ®Google Scholar
• Zhang M, Deng Y, Luo Y, Zhang S, Zou H, Cai F, . Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem. 2012;120:1129–38.
   PubMed Web of Science ®Google Scholar
• Hegde AN. The ubiquitin-proteasome pathway and synaptic plasticity. Learn Mem. 2010;17:314–27.
   PubMed Web of Science ®Google Scholar
• Hegde AN, Inokuchi K, Pei W, Casadio A, Ghirardi M, Chain DG, . Ubiquitin C-terminal hydrolase is an immediate-early gene essential for long-term facilitation in Aplysia. Cell. 1997;89:115–26.
   PubMed Web of Science ®Google Scholar
• Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, . Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006;126:775–88.
   PubMed Web of Science ®Google Scholar
• Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2:a006270.
   PubMed Web of Science ®Google Scholar
• Wang R, Ying Z, Zhao J, Zhang Y, Wang R, Lu H, . Lys(203) and Lys(382) are essential for the proteasomal degradation of BACE1. Curr Alzheimer Res. 2012;9:606–15.
   PubMed Web of Science ®Google Scholar
• Gong B, Chen F, Pan Y, Arrieta-Cruz I, Yoshida Y, Haroutunian V, . SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell. 2010;9:1018–31.
   PubMed Web of Science ®Google Scholar
• He G, Qing H, Tong Y, Cai F, Ishiura S, Song W. Degradation of nicastrin involves both proteasome and lysosome. J Neurochem. 2007;101:982–92.
   PubMed Web of Science ®Google Scholar
• Viswanathan J, Haapasalo A, Bottcher C, Miettinen R, Kurkinen KM, Lu A, . Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formation. Traffic. 2011;12:330–48.
   PubMed Web of Science ®Google Scholar
• Haapasalo A, Viswanathan J, Kurkinen KM, Bertram L, Soininen H, Dantuma NP, . Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation. Commun Integr Biol. 2011;4:428–32.
   PubMedGoogle Scholar
• Lee JE, Jeon IS, Han NE, Song HJ, Kim EG, Choi JW, . Ubiquilin 1 interacts with Orai1 to regulate calcium mobilization. Mol Cells. 2013;35:41–6.
   PubMed Web of Science ®Google Scholar
• Massey LK, Mah AL, Monteiro MJ. Ubiquilin regulates presenilin endoproteolysis and modulates gamma-secretase components, Pen-2 and nicastrin. Biochem J. 2005;391:513–25.
   PubMed Web of Science ®Google Scholar
• He G, Qing H, Cai F, Kwok C, Xu H, Yu G, . Ubiquitin-proteasome pathway mediates degradation of APH-1. J Neurochem. 2006;99:1403–12.
   PubMed Web of Science ®Google Scholar
• Layfield R, Lowe J, Bedford L. The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem. 2005;41:157–71.
   PubMed Web of Science ®Google Scholar
• Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005;280:37377–82.
   PubMed Web of Science ®Google Scholar
• Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, . Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol. 2011;69:248–56.
   PubMed Web of Science ®Google Scholar
• Ohyagi Y. [A drug targeting intracellular amyloid-beta and oxidative stress: Apomorphine]. Rinsho Shinkeigaku. 2011;51:884–7.
   PubMedGoogle Scholar
• Park HM, Kim JA, Kwak MK. Protection against amyloid beta cytotoxicity by sulforaphane: role of the proteasome. Arch Pharm Res. 2009;32:109–15.
   PubMed Web of Science ®Google Scholar